Healthcare and Life Science
Business leader and technologist David Parker joins Amadeus as Venture Partner
Cambridge, UK – Amadeus Capital Partners, the global technology investor, is delighted to welcome Dr. David Parker as a part time Venture Partner to its early stage, deep tech investing team. ...
Lucida Medical Ltd announces a distribution agreement with Sectra to offer Pi AI technology to help diagnose prostate cancer
Lucida Medical announces that it has signed a distribution agreement with international medical imaging IT and cybersecurity company Sectra. Through this agreement, the Lucida Pi application for diagnosing prostate cancer from MRI images will be offered through the Sectra Amplifier Ma...
Enterprise Therapeutics publishes preclinical profile of ETD001, a novel inhaled ENaC blocker
Low doses of ETD001 demonstrate exceptionally long duration of action in sheep model of airway mucus clearance Report in Journal of Cystic Fibrosis discloses best-in-class profile of ETD001 ETD001 scheduled to commence Phase 2 clinical study in people with cystic fibrosis in summe...
Cutting-edge virtual ward wins digital accolade
An initiative by Addenbrooke’s which has enabled more than 1,800 patients to be treated in the comfort of their own homes won a national award on Thursday, 6 June. ...
Newcells Biotech strengthens executive and US team with key appointments
Dr Valeria Chichagova appointed as Director of Technology, Dr Colin Brown as Chief Scientific Officer, and Professor Lyle Armstrong as Scientific Advisor New US commercial appointments also announced to meet growing global demand for products and services Newcastle, UK - New...
Cambridge-based Cofinitive Communications recognised amongst international PR and Communications industry elite
Cambridge-based PR & Comms agency, Cofinitive Communications has been listed in PR Week’s Top 150 PR agency rankings for a third consecutive year. ...
Abzena launches EpiScreen® 2.0 Immunogenicity platform
Abzena launches EpiScreen® 2.0, a next generation immunogenicity tool for de-risking the development of complex biologics and bioconjugates. ...
Abzena announces major investment in Bioconjugation and ADC capabilities
Abzena announces major investment in Bioconjugation and ADC capabilities in response to increasing industry demand. ...
Abzena launches AbZelect CLD platforms
Abzena launches AbZelect™ platforms for improving cell line development efficiency on the pathway to IND. ...
I do not live with diabetes – should I be monitoring my glucose with CGM?
Nowadays, CGMs are being promoted by various biotech companies and social media influencers as tools for understanding and improving health. Unfortunately, I can see a rise in poorly evidenced health messages. In addition, there are many misleading ads risking people’s health. More in ...